1738P - Results from the conference on challenges in sarcoma (CCS) 2024

Background

Guidelines on soft tissue sarcoma (STS) cover aspects, for which evidence exists. However, in the absence of prospective data, conflicting results from retrospective or low-quality studies, controversies remain. Therefore, consensus recommendations are needed to complement guidelines.

Methods

We organized CCS 2024 in St. Gallen, Switzerland. In a modified Delphi process, 200 questions and statements were selected. A consensus was defined as ≥ 75% and a strong consensus as ≥ 95% of votes. During the meeting, cases and controversial topics were discussed. Panellists voted on the questions and statements live during CCS 2024.

Results

Fifty-seven panellists from 13 European countries attended. All specialties involved in STS care and a patient advocate were represented in the panel. Consensus was reached on several topics, e.g. the role of active surveillance in asymptomatic patients with recurrent tenosynovial giant cell tumour (TGCT) or systemic TGCT treatment. The panellists also consented that atypical lipomatous tumours should be treated at certified sarcoma centers, even if the management practices differed between centres. Consensus was found also in offering isolated limb perfusion to patients with unresectable extremity STS who progressed after neoadjuvant chemotherapy, even if patients need referral to an expert centre elsewhere, and in the need of close cooperation between gynaecologists and sarcoma experts in the management of uterine leiomyosarcoma. However, there was no consensus in the management of phyllodes tumours, particularly regarding re-excision versus radiation in case of close resection margins, although not offering adjuvant chemotherapy found consensus. There was also no consensus in the imaging and pathology diagnostics of malignant peripheral nerve sheath tumours in neurofibromatosis patients.

Conclusions

Voting results often reflected varying current practises at different sarcoma centres, yet we were able to identify areas of consensus and topics where future research is needed. Following the discussions during the meeting, the voting on some topics will be repeated online, the results will be presented at ESMO 2024. For some areas, there will probably never be sufficient data or a consensus.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Swiss Cancer Research, Lotte und Adolf Hotz-Sprenger Stiftung, SONK, SWICA, PharmaMar, BAYER, Boehringer Ingelheim, Stadt St. Gallen, Dr. Sennewald, MSD, Deciphera, INNOMEDICA, Blueprint, LINK, SpringWorks,.

Disclosure

C.A. Rothermundt: Financial Interests, Institutional, Advisory Board: Pfizer, Bristol Myers Squibb, IPSEN, PharmaMar; Financial Interests, Institutional, Advisory Role: MSD Oncology. W.G. Kunz: Financial Interests, Personal, Advisory Board: Boehringer Ingelheim, BMS, Need, Inc.; Financial Interests, Personal, Advisory Role: mint Medical. E. Wardelmann: Financial Interests, Personal, Advisory Board: Roche, Bayer, Boehringer Ingelheim Pharma GmbH, Novartis Precision Oncology, Sanofi, PharmaMar; Financial Interests, Personal, Invited Speaker: Asklepios, Bristol Myers Squibb; Financial Interests, Institutional, Funding, reference pathology for E-TRAB study: PharmaMar; Financial Interests, Institutional, Funding, scientific project in the NITRASARC study: Institut für Klinische Krebsforschung am Krankenhaus Nordwest; Financial Interests, Institutional, Trial Chair, organisation of immunohistochemical laboratory ring trials for GIST and sarcoma: Qualitätssicherungs-Initiative Pathologie; Financial Interests, Institutional, Other, reference pathology and molecular analysis: Institut für klinische Krebsforschung; Non-Financial Interests, Member: German Society of Pathology, STBSG in EORTC; Non-Financial Interests, Member, Board of Directors: German Division of International Academy of Pathologists (IAP), German Sarcoma Foundation. P. Rutkowski: Financial Interests, Personal, Invited Speaker, honoraria for lectures: MSD, BMS, Pierre Fabre; Financial Interests, Personal, Advisory Board: MSD, BMS, Pierre Fabre, Merck, Sanofi, Blueprint Medicines, Philogen; Financial Interests, Personal, Invited Speaker: Merck, Sanofi, Novartis, AstraZeneca; Financial Interests, Institutional, Research Grant, research grant for ISS: Pfizer; Financial Interests, Institutional, Funding, research grant for institution: BMS; Non-Financial Interests, Member of Board of Directors: Polish Society of Surgical Oncology; Non-Financial Interests, Member of Board of Directors, President: Polish Oncological Society. P. Reichardt: Financial Interests, Institutional, Advisory Board: Bayer, Deciphera, PharmaMar, Novartis, Boehringer Ingelheim, GSK; Financial Interests, Institutional, Invited Speaker: PharmaMar, Deciphera, Boehringer Ingelheim; Financial Interests, Institutional, Local PI: PharmaMar, Karyopharm, Springworks, AROG, Blueprint, Deciphera, Amgen, Astellas, MSD, Pfizer, Philogen; Financial Interests, Institutional, Coordinating PI: Epizyme, LIlly, Novartis; Non-Financial Interests, Leadership Role: German Sarcoma Foundation. H. Gelderblom: Financial Interests, Institutional, Local PI: Deciphera, Cytovation; Financial Interests, Institutional, Coordinating PI: Boehringer Ingelheim, AmMax Bio, Debiopharm, Abbisko. R.L. Haas: Financial Interests, Institutional, Advisory Board: GSK; Financial Interests, Institutional, Coordinating PI: Novartis, AstraZeneca; Financial Interests, Institutional, Steering Committee Member: Springworks Therapeuticcx; Financial Interests, Institutional, Other, advisory board: PharmaMar. C. Fotopoulou: Financial Interests, Personal and Institutional, Advisory Board: Astra Zeneca, GSK, Roche, Oncoinvent, Ethicon. D. Andreou: Financial Interests, Personal, Invited Speaker: PharmaMar. All other authors have declared no conflicts of interest.